Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

• Status: Completed
• Trial end date: 2011-12-01

Summary

The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer

• Phase: Phase 1

Details

• Lead Sponsor: Pfizer
• Treatments: Capecitabine; Cisplatin; Oxaliplatin; Sunitinib